Apyx Medical (NASDAQ:APYX – Get Free Report) is expected to issue its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect the company to post earnings of ($0.07) per share and revenue of $13.29 million for the quarter. Individuals can check the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Thursday, November 5, 2026 at 8:00 AM ET.
Apyx Medical (NASDAQ:APYX – Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.08) by $0.01. The business had revenue of $13.88 million for the quarter, compared to analysts’ expectations of $13.18 million. Apyx Medical had a negative return on equity of 76.60% and a negative net margin of 14.78%. On average, analysts expect Apyx Medical to post ($0.25) EPS for the current fiscal year and ($0.25) EPS for the next fiscal year.
Apyx Medical Stock Up 4.4%
NASDAQ APYX opened at $2.61 on Thursday. The company has a debt-to-equity ratio of 3.19, a quick ratio of 4.53 and a current ratio of 5.68. The company has a market capitalization of $109.94 million, a P/E ratio of -13.05 and a beta of 1.45. Apyx Medical has a one year low of $2.25 and a one year high of $5.08. The stock has a 50 day moving average price of $2.79 and a 200-day moving average price of $3.62.
Analyst Ratings Changes
A number of equities research analysts recently issued reports on the stock. HC Wainwright began coverage on shares of Apyx Medical in a research note on Monday, July 13th. They set a “buy” rating and a $7.00 price target on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Apyx Medical in a research report on Monday, September 21st. Maxim Group started coverage on shares of Apyx Medical in a research note on Tuesday, September 29th. They issued a “buy” rating and a $6.00 price objective for the company. Finally, Zacks Research upgraded shares of Apyx Medical to a “hold” rating in a report on Tuesday, July 14th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $6.50.
View Our Latest Research Report on Apyx Medical
About Apyx Medical
Apyx Medical Corporation develops and commercializes energy-based medical technologies for use in surgical and aesthetic procedures. The company’s platform is based on helium plasma technology, which is designed to deliver controlled energy for soft-tissue coagulation, cutting, and contraction.
Apyx Medical’s principal product line is Renuvion, a system that combines helium plasma with radiofrequency energy. Renuvion devices and handpieces are used by physicians in a range of surgical and aesthetic applications, including procedures intended to coagulate tissue and address skin laxity.
Further Reading
- Five stocks we like better than Apyx Medical
- Boeing Got Its MAX 10 Approval, But Q3 Delivered a Reality Check
- The Invisible AI Backbone: Corning’s AI Fiber Play
- Heavy Metal: Why Nucor Could Be an Overlooked AI Infrastructure Winner
- Why Tesla’s Upside Is About More Than a SpaceX Merger
Receive News & Ratings for Apyx Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apyx Medical and related companies with MarketBeat.com's FREE daily email newsletter.
